Beijing InnoCare Pharma Tech Co., Ltd.

7 in Phase 3

Quick facts

ICP-022 · Oncology
ICP-022 is a Bruton's tyrosine kinase (BTK) inhibitor that blocks BTK signaling to suppress B-cell and myeloid cell activation in hematologic malignancies.
ICP-332 Tablets · Oncology
ICP-332 is a tyrosine kinase inhibitor that targets specific oncogenic pathways in cancer cells.
ICP-488 · Oncology
ICP-488 is a tyrosine kinase inhibitor that targets FLT3 and other kinases involved in hematologic malignancies.
ICP-488 Tablets · Oncology
ICP-488 is a tyrosine kinase inhibitor that targets mutant EGFR and other kinases involved in cancer cell proliferation.
Orelabrutinib and R-CHOP · Oncology
Orelabrutinib is a Bruton's tyrosine kinase (BTK) inhibitor that blocks the activity of BTK, a protein involved in the activation of B cells.
Orelabrutinib + R-CHOP · Oncology
Orelabrutinib is a Bruton's tyrosine kinase (BTK) inhibitor, and R-CHOP is a chemotherapy regimen that includes rituximab, cyclophosphamide, doxorubicin, and prednisone.
Placebo + R-CHOP · Oncology
This is a Phase 3 trial comparing placebo against R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone), a standard chemotherapy regimen that combines a CD20-targeting monoclonal antibody with multi-agent chemotherapy to treat B-cell lymphomas.

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: